Try our beta test site
10 studies found for:    al-335
Show Display Options
Rank Status Study
1 Completed A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers
Condition: Chronic Hepatitis C
Interventions: Drug: AL-335;   Drug: ACH-3102;   Drug: Simeprevir
2 Completed First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
Condition: Chronic Hepatitis C
Interventions: Drug: AL-335 matching placebo;   Drug: AL-335
3 Recruiting A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335
Condition: Renal Insufficiency
Intervention: Drug: AL-335
4 Completed Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants
Condition: Healthy
Interventions: Drug: AL-335;   Drug: Odalasvir (ODV);   Drug: Simeprevir (SMV)
5 Recruiting A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, ACH-3102, and Simeprevir
Condition: Chronic Hepatitis C
Interventions: Drug: AL-335;   Drug: ACH-3102;   Drug: Simeprevir
6 Completed To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants
Condition: Healthy
Interventions: Drug: Drospirenone/ethinylestradiol;   Drug: AL-335;   Drug: Odalasvir (ODV);   Drug: Simeprevir (SMV)
7 Recruiting Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: AL-335;   Drug: Odalasvir;   Drug: Simeprevir
8 Recruiting A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive
Condition: Hepatitis C, Chronic
Interventions: Drug: AL-335;   Drug: Odalasvir (ODV);   Drug: Simeprevir (SMV)
9 Completed Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants
Condition: Healthy
Interventions: Drug: Odalasvir (ODV);   Drug: AL-335;   Drug: Placebo
10 Recruiting Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)
Condition: Healthy
Interventions: Drug: Simeprevir 75 mg;   Drug: Odalasvir 25 mg;   Drug: Odalasvir 12.5 mg;   Drug: AL-335 800 mg;   Drug: Lansoprazole 30 mg;   Drug: Omeprazole 20 mg

Study has passed its completion date and status has not been verified in more than two years.